These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17297401)

  • 21. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
    Pascual J; van Hooff JP; Salmela K; Lang P; Rigotti P; Budde K
    Transplantation; 2006 Jul; 82(1):55-61. PubMed ID: 16861942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance immunosuppression: new agents and persistent dilemmas.
    Gonin JM
    Adv Ren Replace Ther; 2000 Apr; 7(2):95-116. PubMed ID: 10782729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
    Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric renal transplantation under tacrolimus-based immunosuppression.
    Shapiro R; Scantlebury VP; Jordan ML; Vivas C; Ellis D; Lombardozzi-Lane S; Gilboa N; Gritsch HA; Irish W; McCauley J; Fung JJ; Hakala TR; Simmons RL; Starzl TE
    Transplantation; 1999 Jan; 67(2):299-303. PubMed ID: 10075598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year.
    Mendez R; Gonwa T; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2005 Aug; 80(3):303-9. PubMed ID: 16082323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal.
    Heilman RL; Younan K; Wadei HM; Mai ML; Reddy KS; Chakkera HA; Gonwa TA
    Transplantation; 2011 Oct; 92(7):767-73. PubMed ID: 21775930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualization of immunosuppressive therapy: I. Sirolimus improves outcomes in African-American renal transplant recipients.
    Podder H; Kahan BD
    Transplant Proc; 2005 Nov; 37(9):3723-6. PubMed ID: 16386518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of African-American ethnicity on acute rejection after early steroid withdrawal in primary kidney transplant recipients.
    Padiyar A; Augustine JJ; Bodziak KA; Aeder M; Schulak JA; Hricik DF
    Transplant Proc; 2010 Jun; 42(5):1643-7. PubMed ID: 20620492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression.
    Rajab A; Pelletier RP; Henry ML; Ferguson RM
    Clin Transplant; 2006; 20(5):537-46. PubMed ID: 16968478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized 2×2 factorial trial, part 1: single-dose rabbit antithymocyte globulin induction may improve renal transplantation outcomes.
    Stevens RB; Foster KW; Miles CD; Lane JT; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Nielsen KJ; Skorupa JY; Kellogg AM; Malik T; Wrenshall LE
    Transplantation; 2015 Jan; 99(1):197-209. PubMed ID: 25083614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring.
    Knechtle SJ; Pascual J; Bloom DD; Torrealba JR; Jankowska-Gan E; Burlingham WJ; Kwun J; Colvin RB; Seyfert-Margolis V; Bourcier K; Sollinger HW
    Am J Transplant; 2009 May; 9(5):1087-98. PubMed ID: 19344431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression.
    Mehra MR; Uber PA; Scott RL; Park MH
    Transplantation; 2002 Dec; 74(11):1568-73. PubMed ID: 12490790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients.
    Oh CK; Kim SJ; Kim JH; Lee JH
    J Korean Med Sci; 2012 Apr; 27(4):337-42. PubMed ID: 22468094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No-load sirolimus with tacrolimus and steroids is safe and effective in renal transplantation.
    Tellis V; Schechner R; Mallis M; Rosegreen S; Glicklich D; Moore N; Greenstein S
    Transplant Proc; 2005 Mar; 37(2):906-8. PubMed ID: 15848571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis.
    Michel S; Bigdeli AK; Hagl C; Meiser B; Kaczmarek I
    Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Improved outcome with sirolimus-cyclosporine regimen in high-risk renal transplant recipients].
    Podder H; Forgács B; Csapó Z; Kahan B
    Orv Hetil; 2005 Jul; 146(31):1641-6. PubMed ID: 16158614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.